1. Introduction {#s0005}
===============

Heat shock protein 90 (Hsp90) is an ATP-dependent cellular chaperone responsible for maintaining the stability and activity of a number of client proteins involved in cell signaling, proliferation and survival[@bib1], [@bib2]. Recent studies have shown that Hsp90 is a key protein for oncogenesis and malignancy, and an emerging target for cancer therapeutics[@bib3], [@bib4], [@bib5], [@bib6]. Hsp90 inhibitors can simultaneously inhibit multiple signaling pathways that cancer cells depend on for their growth and proliferation. Since Hsp90 inhibitors have significant potential as antitumor agents, the discovery of Hsp90 inhibitors with new chemical scaffolds is relevant to advances in cancer chemotherapy.

The chaperoning of most Hsp90 client proteins is regulated by a dynamic cycle driven by ATP binding to Hsp90 and subsequent hydrolysis of the protein[@bib7]. The intrinsic ATPase activity of Hsp90 is essential to this activity. Inhibition of the ATPase activity of Hsp90 leads to antitumor activity *in vitro* and *in vivo*[@bib8], [@bib9].

Curcumin is an active ingredient of the plant turmeric (*Curcuma longa*). In our previous work[@bib10], we found that curcumin is a lead compound in the search for new kinds of Hsp90 inhibitors. We thus synthesized a series of derivatives, some of which showed lead-like properties and were found to be more active than curcumin in Hsp90 inhibition and antitumor action[@bib11], [@bib12]. In the present paper, we have investigated a novel curcumin derivative, 3,5-(*E*)-bis(3-methoxy-4-hydroxybenzal)-4-piperidinone hydrochloride (C0818), for its interaction with Hsp90 and its inhibitory effect on the activity of Hsp90 ATPase.

2. Materials and methods {#s0010}
========================

2.1. Materials and reagents {#s0015}
---------------------------

Bacterial strains and plasmids were provided by Prof. Lianru Zhang from School of Life Science, Xiamen University, China. C0818 was designed and synthesized by our laboratory ([Fig. 1](#f0005){ref-type="fig"}). Ni^2+^--nitrilotriacetic acid (NTA) agarose was purchased from General Electric (Little Chalfont, Buckinghamshire, England). ATP was purchased from Sigma--Aldrich (St. Louis, MO, USA). Geldanamycin (GA) was purchased from Shanghai Sangon Biological Engineering (Lot. No. XP0806132012J, Shanghai, China). A stock solution of Hsp90, which was expressed and purified by our laboratory, was prepared in a 10 mmol/L PBS buffer with a pH 7.4, and the applied concentration was fixed at 5.0 μmol/L. C0818 was dissolved in 5% DMSO for fluorescence measurements. The water used in the experiments was thrice-distilled using a Milli-Q Biocel system (Millipore, Bedford, MA, USA). All other reagents were of analytical reagent grade.

2.2. Cloning, expression, and purification Hsp90 {#s0020}
------------------------------------------------

Yeast Hsp90 recombinant plasmid (Hsp90-PET-28a) was used to transform the target constructs of Hsp90 to express in the strain *Escherichia coli* BL21(DE3). The monoclonal cell was picked and cultured in lysogeny broth (LB) at 37 °C. Various constructs of Hsp90, including histidine (his)-tagged yeast full-length Hsp90 (1--732, 90 kDa), the N-terminal domain of Hsp90 (N-Hsp90, 1--236, 25 kDa), the middle domain of Hsp90 (M-Hsp90, 272--617, 40 kDa) and the C-terminal domain of Hsp90 (C-Hsp90, 629--732, 15 kDa), were induced by IPTG (isopropyl *β*-[d]{.smallcaps}-1-thiogalactopyranoside) and expressed in bacterial strains and purified by Ni^2+^-NTA (nitrilotriacetic acid) and gel filtration[@bib13].

2.3. *Fluorescent measurements* {#s0025}
-------------------------------

Samples were excited at 280 nm and fluorescence intensities were recorded in the range of 290--500 nm at 293, 303 and 310 K, respectively, using a Cary Eclipse (Varian, Palo Alto, CA, USA). Fluorometric titration experiments were performed in 2.0 mL of 5.0 μmol/L Hsp90 solution (10 mmol/L PBS buffer, pH 7.6) with successive additions of C0818 solution (in 0.2% DMSO) from 5.0 to 50 μmol/L. All tests were performed in triplicate[@bib14].

2.4. Hsp90 ATPase activity assay {#s0030}
--------------------------------

The reaction was performed in 100 μL of assay buffer (6 mmol/L MgCl~2~, 20 mmol/L KCl and 100 mmol/L Tris--HCl, pH 7.4) containing 0.4 μmol/L Hsp90, 1 mmol/L ATP and different concentrations of C0818 or GA or vehicle (DMSO) and incubated at 310 K for 3 h. At the end of the incubation, the ATPase activity of Hsp90 were assessed by malachite green reagent (0.0812% *w/v* malachite green, 2.32% *w/v* polyvinyl alcohol and 5.72% *w/v* ammonium molybdate in 6 mol/L HCl, and argon water mixed in a ratio of 2:1:1:2, *v/v/v/v*). Cultures were analyzed in triplicate at an absorbance of 620 nm[@bib13]. The kinetic analysis of the Hsp90 ATPase activity was carried out using a nonlinear regression fit of the experimental points to the Michaelis--Menten equation. To obtain *K*~m~ and *V* values, the Eadie--Hofstee linear transformation (*V* against *V*/\[*s*\]) was used, with the slope=−*K*~m~ and the intercept on the *x* axis=*V*/*K*~m~[@bib13].

2.5. Statistical analysis {#s0035}
-------------------------

All data were analyzed with two-sided unpaired *t*-test in the GraphPad software package for Windows (Prism version 5.0) and Origin8.5 software. Values are expressed as means of triplicate or duplicate experiments.

3. Results {#s0040}
==========

3.1. The interaction between C0818 and Hsp90 {#s0045}
--------------------------------------------

### 3.1.1. C0818 quenched the intrinsic fluorescence of Hsp90 {#s0050}

The binding of C0818 to Hsp90 was characterized by fluorescence quenching. At excitation wavelength of 280 nm, the interaction was examined with fluorescence spectrum from 290 to 510 nm. His-tagged Hsp90 displayed maximal fluorescence at 334 nm. When Hsp90 was incubated with increasing concentrations of C0818, the fluorescence intensity gradually decreased with a slight blue shift of *λ*~em~ ([Fig. 2](#f0010){ref-type="fig"}A).

The dissociation constants (*K*~D~) is calculated by the equation:$$\Delta F = F_{0} - F = F_{max}\left\lbrack Q \right\rbrack/K_{D} + \left\lbrack Q \right\rbrack$$where *F*~0~ is the steady-state fluorescence intensity of Hsp90, *F* is the fluorescence intensity of Hsp90 in presence of C0818 at different concentrations, and \[*Q*\] is the concentration of C0818. The titration curves for Hsp90 yields estimated dissociation constants (*K*~D~) of C0818 for Hsp90, which is of 23.41±0.94 μmol/L ([Fig. 2](#f0010){ref-type="fig"}B), indicating that C0818 quenched the intrinsic fluorescence of Hsp90 and that there was a binding interaction between them[@bib15] ([Table 1](#t0005){ref-type="table"}).

### 3.1.2. Quenching constant and quenching rate constant {#s0055}

The quenching process can be analyzed by Stern--Volmer equation:$$F_{0}/F = 1 + K_{sv}\left\lbrack Q \right\rbrack = 1 + K_{q}^{\tau_{0}}\left\lbrack Q \right\rbrack$$where *F*~0~, *F* and \[*Q*\] means the same as in Eq. [(1)](#eq0005){ref-type="disp-formula"}, *K*~SV~ is the Stern--Volmer quenching constant in static quenching, *K*~q~ is the quenching rate constant, and *τ*~0~ is endogenous fluorescence lifetime value of biological macromolecules[@bib16], which generally is 10^−8^ s. *K*~sv~ and *K*~q~ were obtained from the slope of *F*~0~/*F* plotted against \[*Q*\] ([Fig. 2](#f0010){ref-type="fig"}C) and the results are listed in [Table 2](#t0010){ref-type="table"}.

The maximum dynamic collisional quenching constant of all kinds of quenching agent with biopolymers is 2.0×10^10^ L/mol/s, the quenching rate constant *K*~q~ of C0818 was greater than 2.0×10^10^ L/mol/s, indicating that the quenching effect of C0818 on intrinsic fluorescence of Hsp90 is not due to molecules collision in dynamic quenching, but due to the formation of complex in static quenching[@bib17].

### 3.1.3. Number of binding sites and constant {#s0060}

Static quenching complies with the Lineweaver--Burk equation[@bib18]:$${Lg} F_{0}–F/F = {Lg} K + n{Lg}\left\lbrack Q \right\rbrack$$where *F*~0~, *F* and \[*Q*\] means the same as in Eq. [(1)](#eq0005){ref-type="disp-formula"}, *K*~A~ is the apparent binding constant, and *n* is the binding site. *K*~A~ and *n* were obtained from the intercept and slope of lg*F*~0~ --*F*/*F* plotted against lg\[*Q*\] ([Fig. 2](#f0010){ref-type="fig"}D), respectively, and the results are listed in [Table 3](#t0015){ref-type="table"}.

### 3.1.4. Thermodynamic parameters {#s0065}

Over the temperature ranges examined and when the thermodynamic enthalpy change (Δ*H*^*θ*^) did not vary significantly, van׳t Hoff׳s equation was used to obtain the values of Δ*H*^*θ*^ and entropy change (Δ*S*^*θ*^*)*:$${Ln} K_{D1}/K_{D2} = \Delta H^{\theta}\left( {1/T_{l}–1/T_{2}} \right)/R$$$$\Delta G^{\theta} = \Delta H^{\theta}–T\Delta S^{\theta} = RT{Ln}K_{D}$$where R is the thermodynamic gas constant and the value is 8.314 J/mol/K, *T* is thermodynamic temperature, *K*~D~ is corresponding dissociation constants at different temperatures, Δ*G*^*θ*^ is Gibbs free energy change. Fluorescence intensities were recorded in the range of 290--510 nm at 293, 303 and 310 K, respectively ([Fig. 3](#f0015){ref-type="fig"}).

The thermodynamic enthalpy change (Δ*H*^*θ*^), entropy change(Δ*S*^*θ*^) and free energy change (Δ*G*^*θ*^) of C0818--Hsp90 binding were also calculated from the fluorescent spectrum, the results are listed in [Table 4](#t0020){ref-type="table"}. The negative enthalpy change and positive entropy change suggest that electrostatic interaction predominated in stabilizing the C0818--Hsp90 complex[@bib19].

In order to further determine the interaction type between C0818 and Hsp90, a synchronous fluorescence method was used to study the impact of C0818 on Hsp90 conformation.

### 3.1.5. Impact of C0818 on Hsp90 conformation {#s0070}

Tyrosine (Tyr) and tryptophan (Trp) are the main source of protein fluorescence. When the D-value (Δ*λ*) between excitation and emission wavelengths was stabilized at 15 or 60 nm, the synchronous fluorescence provided the characteristic information of Tyr or Trp residues.

When Δ*λ* was 15 or 60 nm, increasing concentrations of C0818 led to a dramatic decrease in fluorescence intensity, but the fluorescence peak position of Tyr or Trp residues remained the same ([Fig. 4](#f0020){ref-type="fig"}), indicating that the microenvironment of Tyr or Trp residues did not change after binding, and that the hydrophobic microenvironment did not obviously decrease. These results imply that the conformation of Tyr or Trp of Hsp90 did not change.

### 3.1.6. The domain of Hsp90 binding C0818 {#s0075}

The domain of Hsp90 involved in binding C0818 was determined by constructing three truncation mutants: N-Hsp90, M-Hsp90 and C-Hsp90, corresponding to its ATP-binding domain, its co-chaperone binding domain and its dimerization domain. The fluorescence intensity of C-Hsp90, but not N-Hsp90 or M-Hsp90, was the most obviously quenched with increasing concentrations of C0818, indicating that C0818 may interact with the C-terminal domain ([Fig. 5](#f0025){ref-type="fig"}). The dissociation constant *K*~D~ values are listed in [Table 5](#t0025){ref-type="table"}.

3.2. C0818 inhibits the ATPase activity of Hsp90 {#s0080}
------------------------------------------------

To characterize the inhibition of Hsp90 by C0818 binding, a colorimetric assay for inorganic phosphate was used to measure the inhibitory effect of C0818 on the ATPase activity of Hsp90. This assay is based on the formation of a phosphomolybdate complex and a subsequent reaction with malachite green. When the concentration of ATP was 1 mmol/L, the IC~50~ values of C0818 and GA were 120.74 and 0.41 μmol/L, respectively. [Fig. 6](#f0030){ref-type="fig"} demonstrates the inhibition of Hsp90 ATPase activity by C0818. GA is a potent antiproliferative agent but is not an ideal clinical agent due to its marked hepatotoxicity and narrow therapeutic window[@bib9]. C0818, a small-molecule inhibitor, may have potential as a therapeutic agent with improved pharmacological properties compared to GA.

4. Discussion {#s0085}
=============

Quenching of the fluorescence from a macromolecule can be classified as static quenching or dynamic quenching. In static quenching, the stability of new complexes of quenching agent and fluorescent material results in the decrease of the quenching constant of fluorescence. In dynamic quenching, the excited state molecules of quenching agent and fluorescent material collide with each other, resulting in energy transfer[@bib20].

Our data suggest that C0818 is an Hsp90 inhibitor. Compared with the known inhibitor GA, C0818 has a novel scaffold unrelated to that of any other known Hsp90 inhibitor. Spectroscopic methods were used to study the interaction between C0818 and full-length Hsp90, N-Hsp90, M-Hsp90 and C-Hsp90. From the binding energy and dissociation constants, we demonstrated that C0818 is an inhibitor of Hsp90 and that it binds to the C-terminal dimerization domain of Hsp90. The quenching effect of C0818 on Hsp90 intrinsic fluorescence can thus be classified as static quenching. The thermodynamic parameters and the synchronous fluorescence suggest that electrostatic interactions predominate in stabilizing the C0818--Hsp90 complex.

C0818 inhibits the ATPase activity of Hsp90, so the binding of C0818 inhibits the catalysis of ATP hydrolysis. The binding of Hsp90 pockets arrests the catalytic cycle of Hsp90 in the ADP-bound conformation. The affinity-based screen showed that C0818 binds to Hsp90, therefore confirming the interaction between Hsp90 and C0818. In the assay measuring ATPase activity of Hsp90, C0818 demonstrated dose-dependent inhibition of the ATPase activity of Hsp90. As expected, the positive control GA also showed dose-dependent inhibition in this system.
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![Chemical structure of C0818.](gr1){#f0005}

![C0818 physically binds to Hsp90. (A) Quenching effect of C0818 (0--50 μmol/L) on Hsp90 endogenous fluorescent in a concentration-dependent manner. The maximal fluorescence displayed at 334 nm. (B) The change trend of Hsp90 fluorescence intensity with C0818 concentration. (C) Stern--Volmer plot for the binding of C0818 with Hsp90. (D) Lineweaver--Burk plot for the binding of C0818 with Hsp90.](gr2){#f0010}

![Quenching effect of C0818 (0--50 μmol/L) on Hsp90 endogenous fluorescent at different temperatures (293, 303 and 310 K).](gr3){#f0015}

![Synchronous fluorescence spectra of C0818 (0--50 μmol/L) with Hsp90. (A) ∆*λ* = 15 nm; (B) ∆*λ* = 60 nm.](gr4){#f0020}

![Quenching effect of C0818 (0--50 μmol/L) on endogenous fluorescent of N-Hsp90, M-Hsp90 and C-Hsp90.](gr5){#f0025}

![The inhibition rate of Hsp90 ATPase activity under different concentrations of C0818 (0--200 μmol/L).](gr6){#f0030}

###### 

Dissociation constant *K*~D~ values of C0818 and geldanamycin (GA).

Table 1

  Compound   *F*~max~      *K*~D~ (μmol/L)   *R*^2^
  ---------- ------------- ----------------- --------
  GA         546.16±7.92   24.39±0.79        0.999
  C0818      329.93±5.79   23.41±0.94        0.999

###### 

The Stern--Volmer quenching constant *K*~sv~ and bimolecular quenching constant *K*~q~ of C0818 and GA.

Table 2

  Compound   *K*~q~ (L/mol/s)     *K*~sv~ (L/mol)     *R*^2^
  ---------- -------------------- ------------------- --------
  GA         (7.67±0.44)×10^12^   (7.67±0.44)×10^4^   0.968
  C0818      (1.49±0.12)×10^13^   (1.49±0.12)×10^5^   0.943

###### 

The binding constant *K*~A~ and the binding number *n* of C0818 and GA.

Table 3

  Compound   *K*~A~ (L/mol)   *n*         *R*^2^
  ---------- ---------------- ----------- --------
  GA         2.88×10^5^       1.14±0.04   0.986
  C0818      1.04×10^7^       1.44±0.05   0.989

###### 

Dissociation constant *K*~D~ and thermodynamic parameters of C0818 and GA at different temperatures.

Table 4

  Compound   *T* (K)      *K*~D~ (μmol/L)   *R*^2^        Δ*G*^*θ*^ (kJ/mol)   Δ*H*^*θ*^ (kJ/mol)   Δ*S*^*θ*^ (J/mol/K)
  ---------- ------------ ----------------- ------------- -------------------- -------------------- ---------------------
  GA         293          18.63±0.79        0.999         −26.53±0.11          −11.20±2.42          52.32±8.00
  303        22.42±0.65   0.999             −26.97±0.07                                             
  310        24.39±0.80   0.999             −27.37±0.08                                             
  C0818      293          39.13±0.91        0.999         −24.72±0.06          −12.96±0.74          40.27±2.45
  303        46.44±1.72   0.999             −25.13±0.09                                             
  310        53.44±2.28   0.998             −25.35±0.11                                             

###### 

Dissociation constant *K*~D~ of C0818 and GA.

Table 5

  Interaction      *F*~max~      *K*~D~ (μmol/L)   *R*^2^
  ---------------- ------------- ----------------- --------
  N-Hsp90--GA      221.22±4.91   5.84±0.61         0.991
  M-Hsp90--GA      158.20±1.68   42.13±0.80        0.999
  C-Hsp90--GA      67.91±0.63    36.72±0.64        0.999
  N-Hsp90--C0818   159.48±3.15   38.15±1.40        0.999
  M-Hsp90--C0818   232.46±3.46   24.52±0.82        0.999
  C-Hsp90--C0818   76.51±1.35    13.51±0.68        0.998
